{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:03:00Z","timestamp":1766181780812,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: The results of long-term renal evolution in HCV-infected patients using sofosbuvir and velpatasvir (SOF\/VEL), with or without ribavirin (RBV), are lacking. Aims: We evaluated the renal safety for HCV-infected patients receiving SOF\/VEL. Methods: Between 1 June 2019 and 6 July 2020, we included 594 HCV-infected patients receiving SOF\/VEL +\/\u2212 RBV for 12 weeks in Taiwan. Viral eradication rate (defined by sustained virological response at week 12 post-treatment; SVR12) and changes to renal function were considered. Results: SVR12 was achieved in 99.3% (590\/594) upon per-protocol analysis. Patients saw improved hepatobiliary function and fibrosis after the start of SOF\/VEL therapy. For renal function, those with baseline estimated glomerular filtration rate (eGFR) \u2265 60 (mL\/min\/1.73 m2) experienced transient on-treatment reduction in renal function that improved upon ending treatment, but recurrent eGFR degradation during one-year follow-up. The use of RBV (OR = 5.200, 95% CI: 1.983\u201313.634, p = 0.001) was a significant risk factor at SVR24, while diabetes mellitus (OR = 2.765, 95% CI: 1.104\u20136.922, p = 0.030) and the use of RBV (OR = 3.143, 95% CI: 1.047\u20139.435, p = 0.041) were identified as significant risk factors of worsening renal function at SVR48. SOF\/VEL did not worsen renal function among those with stage 4\u20135 chronic kidney disease (CKD) who were not receiving dialysis. Conclusions: A trend of decline in eGFR at 1 year after SOF\/VEL treatment was observed among diabetic patients with baseline eGFR \u2265 60 (mL\/min\/1.73 m2) and concomitant use of RBV. The close monitoring of renal function is warranted. Further study should be conducted in order to weigh the risks and benefit of RBV.<\/jats:p>","DOI":"10.3390\/v14020362","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:40:17Z","timestamp":1644547217000},"page":"362","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4105-4913","authenticated-orcid":false,"given":"Cheng-Kun","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-2275","authenticated-orcid":false,"given":"Li-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung 20420, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-6948","authenticated-orcid":false,"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Chiayi 613016, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-Yi","family":"Tung","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Chiayi 613016, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-3190","authenticated-orcid":false,"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou 333423, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung 20420, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou 333423, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shyan","family":"Sheen","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou 333423, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"unstructured":"Polaris Observatory HCV Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176.","key":"ref_1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Jordan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12072-019-09974-z","article-title":"Direct-acting antivirals in East Asian hepatitis C patients: Real-world experience from the REAL-C Consortium","volume":"13","author":"Huang","year":"2019","journal-title":"Hepatol. Int."},{"doi-asserted-by":"crossref","unstructured":"Mangia, A., Piazzolla, V., Giannelli, A., Visaggi, E., Minerva, N., Palmieri, V., Carraturo, I., Potenza, D., Napoli, N., and Lauletta, G. (2019). SVR12 rates higher than 99% after sofosbuvir\/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS ONE, 14.","key":"ref_8","DOI":"10.1371\/journal.pone.0215783"},{"doi-asserted-by":"crossref","unstructured":"Buggisch, P., Wursthorn, K., Stoehr, A., Atanasov, P.K., Supiot, R., Lee, J., Ting, J., and Petersen, J. (2019). Real-world effectiveness and safety of sofosbuvir\/velpatasvir and ledipasvir\/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS ONE, 14.","key":"ref_9","DOI":"10.1371\/journal.pone.0214795"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.14799","article-title":"Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: An ERCHIVES study","volume":"48","author":"Butt","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0168-8278(18)30262-9","article-title":"Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: A retrospective longitudinal study","volume":"68","author":"Mallet","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","article-title":"Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals","volume":"72","author":"Liu","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J. Hepatol."},{"doi-asserted-by":"crossref","unstructured":"Chiu, S.-M., Tsai, M.-C., Lin, C.-Y., Chen, C.-H., Lu, S.-N., Hung, C.-H., Sheen, I.-S., Chien, R.-N., Lin, C.-L., and Hu, T.-H. (2020). Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. PLoS ONE, 15.","key":"ref_16","DOI":"10.1371\/journal.pone.0231102"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/23744235.2018.1535186","article-title":"Sofosbuvir\/velpatasvir for the treatment of HCV: Excellent results from a phase-3, open-label study in Russia and Sweden","volume":"51","author":"Isakov","year":"2019","journal-title":"Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient-reported outcomes with sofosbuvir and velpatasvir with or without RBV for hepatitis C virus-related decompensated cirrhosis: An exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial","volume":"1","author":"Younossi","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of Sofosbuvir and Velpatasvir, With and Without RBV, in Patients with Hepatitis C Virus Genotype 3 Infection and Cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir-velpatasvir with RBV for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"},{"doi-asserted-by":"crossref","unstructured":"Mangia, A., Cenderello, G., Copetti, M., Verucchi, G., Piazzolla, V., Lorusso, C., Santoro, R., Squillante, M.M., Orlandini, A., and Minisini, R. (2019). SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF\/VEL without RBV: A Nation-Wide Cohort Study. Cells, 8.","key":"ref_23","DOI":"10.3390\/cells8040313"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12072-018-9878-6","article-title":"Sofosbuvir-velpatasvir plus RBV in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals","volume":"12","author":"Izumi","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","article-title":"Efficacy and safety of sofosbuvir-velpatasvir with or without RBV in HCV-infected Japanese patients with decompensated cirrhosis: An open-label phase 3 trial","volume":"54","author":"Takehara","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17512433.2018.1451327","article-title":"Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: A review on incidence, type and risk factors","volume":"11","author":"Khalili","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12072-018-9915-5","article-title":"APASL clinical practice recommendation: How to treat HCV-infected patients with renal impairment?","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_28","first-page":"396A","article-title":"Direct-acting antiviral treatment patterns among hepatitis C patients with advanced chronic kidney disease: A retrospective cohort study","volume":"62","author":"Singer","year":"2016","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease: A systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol. J."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/362\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:17:33Z","timestamp":1760134653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["v14020362"],"URL":"https:\/\/doi.org\/10.3390\/v14020362","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}